Investigator
Salwa A Elgebaly
NOUR HEART, INC. · funded by NHLBI
- Companies
- 2
- Grants
- 2
- Non-dilutive funding
- $2.0M
- First award
- Sep 20, 2024
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
On this record.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- NOUR HEART, INC.Momentum in another area
Grant-only
- NOUR HEART, INC.Momentum in another area
Grant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R44
Nourexal™: A Novel Bioenergetic Drug to Increase Donor Heart Utilization
$50kSep 20, 2024NHLBINOUR HEART, INC.NIH RePORTER · 11209264 (opens the source filing in a new tab)
- R44
Nourexal™: A Novel Bioenergetic Drug to Increase Donor Heart Utilization
$1.9MSep 20, 2024NHLBINOUR HEART, INC.NIH RePORTER · 11194294 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources